ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Also written as “Infanrix hexa”, “DTPa-HBV-IPV/Hib” and “Infanrix™ hexa”.

Its studies are mostly in Hepatitis B · Diphtheria · Streptococcal Infections · Poliomyelitis · Meningococcal Infections, led by 4 companies.

Drug pageDiphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 29, 200827 company-led studies, 2 open or runningNext primary completion: May 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only230 open or runningphase 4since Jan 29, 2008Sep 13, 2005none ahead
Pfizer21 open or runningphase 4since Feb 17, 2006Feb 17, 2006Nov 6, 2028phase 3 · NCT07160244
Merckits history only10 open or runningphase 3since Feb 5, 2007Feb 5, 2007none ahead
Sanofiits history only11 open or runningphase 2since Oct 16, 2024Oct 16, 2024May 17, 2027phase 2 · NCT06647407

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2006First study: phase 4 study in FeverFirst studyNCT00294294 · 300 enrolled
  2. Aug 14, 2025Phase 3 study in HealthyNCT07160244 · 6,000 planned · United States, Argentina, Brazil and more

Ahead

  1. Nov 6, 2028Primary completion: phase 3 study in HealthyNCT07160244

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 2 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07160244Healthy · United States, Argentina, Brazil and more3RecruitingNov 6, 20286,000
NCT00294294Fever4CompletedDec 2006300

How it is read

Names in the registry

  • “Infanrix hexa”, 10 entries
  • “DTPa-HBV-IPV/Hib”, 3 entries
  • “Infanrix™ hexa”, 3 entries
  • “Infanrix Hexa”, 2 entries
  • “DTPa-HBV-IPV/Hib (Infanrix hexa™)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.